Dr David Meininger | Chief Business Officer
Trianni Inc

Dr David Meininger, Chief Business Officer, Trianni Inc

Dr. Meininger was previously Executive Director, Business Development & Licensing with Merck where he had global responsibility for biologics technologies as a member of the West Coast Innovation Hub. Prior to his transition to business development, he led Protein Science and managed biologic lead generation for immuno-oncology and other programs that progressed to development and onto market. At Amgen, he served on multiple teams that advanced programs from discovery through the clinic. Dr. Meininger completed his postdoc in Protein Engineering at Genentech, received his PhD from UCSD and his MBA from The University of Washington.

Appearances:



EAC 2017 Day 2, Wednesday 1st November 2017 @ 11:45

Exceptional human antibody discovery with a best-in-class transgenic mouse

  • Examine a unique transgenic platform: expression of a complete human antibody variable domain repertoire drive by optimized murine genetic sequence – The Trianni Mouse.
  • Review licensee case studies and internal validation data
  • Learn about future strains and modifications under development
 

back to speakers